Mechanisms of arterial calcifications and consequences for cardiovascular function

Gérard M. London¹

¹INSERM U970 Paris, and Nephrology Department Manhé's Hospital, Fleury-Mérogis, France

Cardiovascular complications are the leading cause of mortality in chronic (CKD) and end-stage renal disease (ESRD). The risk of developing cardiovascular complications is associated with changes in the structure and function of the arterial system, which are in many aspects similar to those occurring with aging. The presence of traditional risk factors does not fully explain the extension and severity of arterial disease. Therefore, other factors associated with CKD and ESRD must also be involved. Arterial calcification (AC) is a common complication of CKD and ESRD, and the extent of AC in general population as well as in patients with CKD is predictive of subsequent cardiovascular mortality beyond established conventional risk factors. AC is an active process similar to bone formation that implicates a variety of proteins involved in bone and mineral metabolism and is considered part of a systemic dysfunction defined as CKD-associated mineral and bone disorder (CKD-MBD).

MECHANISMS OF AC
Long time considered a passive process associated with cellular aging and death, and high extracellular fluid calcium-phosphate concentrations, the results of many recent studies have indicated that cardiovascular calcifications are an active process, in many aspects similar to embryonic bone formation, which is regulated by a variety of genes and proteins implicated in mineral and bone metabolism. This process involves differentiation of contractile vascular smooth muscle cells (VSMCs), and pericytes into distinct, ‘osteoblast-like’ cells with a secretory phenotype. VSMC synthesize bone-associated proteins, including alkaline phosphatase, osteocalcin, osteopontin, and a coat of collagen-rich extracellular matrix, via the formation of matrix vesicles, nodules, and apoptotic bodies, which serve as initiation sites for apatite nanocrystal deposition (but also with bone formation and real ossification). Clinical and experimental data show that this process can be triggered by many factors including dyslipidemia, oxidative stress, advanced glycation end-products and hyperglycemia, hyperphosphatemia, increased serum aldosterone levels, and age-associated cellular senescence. These risk factors have in common that they all converge to a final pathway, that is, inflammation and nuclear factor (NF)-κB activation. Molecular imaging in vivo has demonstrated inflammation-associated osteogenesis in early-stages of atherosclerosis, confirming the role of inflammation in triggering the metabolic cascade leading to the transformation of VSMC into an osteogenic phenotype. Macrophage activation releases proinflammatory cytokines (such as interleukin-6 and tumor necrosis factor-α), and proteolytic enzymes (matrix metalloproteinase-2, matrix metalloproteinase-9,
and cathepsin S) whose release is associated with osteochondrogenic VSMC transdifferentiation. Interleukin-6 and tumor necrosis factor-α are the first steps for the activation of BMP2:BMP4 and Msx2, which promotes calcification by activating paracrine Wnt signals and nuclear activation and localization of β-catenin, an indispensable coregulator of expression of Runx2, osterix, and Sox9, which are all transcription factors associated with the osteochondrogenic phenotype conversion of VSMC and pericytes. The second aspect of inflammation-related calcification is the proteolytic activation of elastolysis and degradation of extracellular matrix. The fragmentation of elastic lamellae and release of biologically active elastin-derived peptides also promote VSMC dedifferentiation and calcium deposition.

Aging is the most typical condition associated with the development of vascular calcifications. VSMC senescence is associated with the switch to a secretory phenotype (senescence-associated secretory phenotype) that initiates osteoblastic transition with calcifications and artery-wall remodeling. Senescence-associated secretory phenotype is linked to low-grade arterial inflammation with increased NF-κB activation. NF-κB activity, inflammation, and excessive production of reactive oxygen species are associated with several features of the progeroid syndrome such as accumulation of prelamin A, low telomerase activity and telomere shortening, and DNA damage, all conditions being associated with the development of an osteogenic program and AC.

In vitro, calcium and phosphate promote both synergistically and independently VSMC calcification. Recent findings indicate that hyperphosphatemia, through activation of mitochondrial respiration, stimulates the production of reactive oxygen species with final activation of NF-κB, enhancing Runx2 (Cbfa1) activation and matrix vesicle release and promoting the differentiation of mesenchymal cells into osteoblastic lineage.

In presence of normal serum, VSMC do not calcify. Serum inhibits spontaneous calcium and phosphate precipitation in solution, indicating that systemic calcification inhibitors are present in the serum and also in VSMC, which constitutively express potent local or systemic inhibitors of calcification, such as matrix GLA protein, which may limit AC by binding to bone morphogenic proteins. Osteopontin and osteoprotegerin are potent inhibitors of AC in vivo, and inactivation of their genes enhances the calcification process. Fetuin-A (AHSG or 2-HS glycoprotein) is a potent circulating AC inhibitor that is abundant in plasma. Pyrophosphate is another potent inhibitor. In vitro, phosphate-stimulated apatite production can be completely prevented by adding pyrophosphates.

In CKD and ESRD patients, the relationships between AC and changes in phosphate and calcium homeostasis are associated with disruption of endocrine and humoral pathways, including parathyroid hormone (PTH), calcitriol, and the fibroblast growth factor-23—Klotho–vitamin D axis. The increase in bone resorption observed in CKD patients with secondary hyperparathyroidism is frequently associated with AC. Excessive phosphate and calcium efflux from bone probably has an important role. The direct intervention of PTH is less clear. Chronically elevated PTH upregulates RANKL, downregulates OPG gene expression, and raises the RANKL/OPG ratio. However, intermittent increases in serum PTH exert an anabolic action on bone, and intermittent PTH administration has been shown to prevent AC. Low Klotho expression and resistance to the phosphaturic effect of fibroblast growth factor-23 are also associated with AC.

CLINICAL IMPACT OF ACs

Both intima and media calcifications are associated with increased morbidity and mortality, but they alter arterial functions by different pathological mechanisms. Intima plaque calcification occurs in the context of common atherosclerosis. Intima calcification induces arterial dysfunction resulting from the narrowing of the arterial lumen with ischemia affecting the tissues and organs downstream. As calcification advances with the progression of atherosclerosis, it is uncertain whether the calcification itself represents a risk factor or whether it is only a surrogate marker of plaque burden and disease extension. Acute coronary events and myocardial infarction are more related to the biomechanical stability of atherosclerotic plaques and rupture of the fibrous cap of the plaque. Although a higher coronary AC score is associated with a poorer cardiovascular prognosis, the influence of calcification on plaque stability is controversial. The results of several studies indicate that AC does not increase plaque vulnerability, which seems more attributable to a large lipid pool, thin fibrous cap, and intensity of local inflammation.

Media calcification (Mönckeberg’s sclerosis or/media calcinosis) is characterized by diffuse mineral deposits within the arterial tunica media. Media calcification is concentric, not extending into arterial lumen in its typical pure form and is associated with abnormal cushioning function of blood vessels (arteriosclerosis–arterial hardening) by promoting arterial stiffness. The first, principal consequence of arterial stiffening is increased systolic pressure, resulting in elevated cardiac afterload and left ventricular hypertrophy. The second consequence is decreased diastolic pressure and impaired coronary perfusion. As the two forms of AC are frequently associated in patients with CKD abnormalities of conduit and cushioning function are often associated as well.

MANAGEMENT AND PREVENTION

Several experimental studies have shown that the development of AC calcification can be prevented or delayed by several interventions such as treatment with pyrophosphates, inhibition of receptor activator of NF-κB, treatment with bisphosphonates, cinacalcet, angiotensin-converting enzyme inhibitors, and mineralocorticoid receptor antagonists, and inhibition of bone morphogenic proteins signaling.
Regression of AC is rarely observed in humans; therefore, the primary goal is prevention and stabilization of existing calcifications. As intimal AC are related to atherosclerosis, the general approach is nonspecific, as advocated for patients with atherosclerosis: control of blood lipids (but no evidence of a benefit with statins), use of aspirin, treatment of obesity and hypertension, increase in physical activity, cessation of smoking, and optimal control of diabetes. More specific preventive measures for patients with CKD and ESRD include controlling serum calcium and phosphate levels, thereby avoiding hypercalcemia and hyperphosphatemia. Prevention of hyperphosphatemia is based on the diet, increased dialysis efficiency and the prescription of phosphate binders, with the preference for non-calcium-containing binders. Calcium-containing phosphate binders should be avoided or prescribed carefully in patients with permanently low PTH, presence of extensive ACs (old patients), and hypercalcemia. Hypercalcemia and calcium overload are associated with the progression of AC, 62 oversuppression of PTH, and adynamic bone disease. Oversuppression of PTH and adynamic bone disease are frequently associated with AC 63 and should be avoided. Positive calcium balance could be induced by high dialysate calcium concentrations, pharmacological doses of active vitamin D, and calcium-containing phosphate binders. Severe secondary hyperparathyroidism is associated with AC and bone resorption-associated calcium and phosphates release, with hypercalcemia and hyperphosphatemia. In these conditions, the prescription of cinacalcet seems the preferable pharmacological treatment. 64 Some endogenous calcification inhibitors such as matrix GLA protein are vitamin K dependent. Dialysis patients have vitamin K deficiency and increased levels of inactive dephosphorylated-uncarboxylated matrix GLA protein, which could be reduced by daily vitamin K2 suplementations. 65,66 The efficiency of vitamin K2 supplementation on AC is under study. Considering these interrelationships, the benefit of warfarin prescription in ESRD patients should be carefully weighed against potential risk.

In conclusion, AC is an active process associated with phenotype transition of VSMCs to osteoblast-like cells. This transition is associated with disrupted balance between factors inducing calcifications and those preventing it. The principal disorders associated with development of vascular calcifications in CKD/ESRD are phosphorus retention in association with positive calcium balance, and decreased activity of factors preventing calcification process.

ACKNOWLEDGMENTS
This supplement was supported by a grant from the 58th Annual Meeting of the Japanese Society for Dialysis Therapy.

DISCLOSURE
GML has received consulting and lecture fees from Amgen and Bayer, and has received consulting fees from Servier.

REFERENCES
1. Briet M, Boutouyrie P, Laurent S et al. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int 2012; 82: 383–400.
2. London GM, Druke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51: 1678–1695.
3. Blacher J, Guérin AP, Pannier B et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434–2439.
4. Goodman WG, Goldin J, Kuizon BD et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. New Engl J Med 2000; 342: 1478–1483.
5. Guérin AP, London GM, Marchais SJ et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014–1021.
6. Shroff RC, McNair R, Figg N et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008; 118: 1748–1757.
7. Wilson PWF, Kauppila LI, O’Donnell CJ et al. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 2001; 103: 1529–1534.
8. London GM, Guérin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731–1740.
9. O’Rourke MF. Mechanical principles in arterial disease. Hypertension 1995; 26: 2–9.
10. O’Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005; 46: 200–204.
11. Demer LL, Tintut Y. Vascular calcification: pathobiology of multifaceted disease. Circulation 2008; 117: 2938–2948.
12. Schoppet M, Shroff RC, Hofbauer LC et al. Exploring the biology of vascular calcification in chronic kidney disease: what’s circulating? Kidney Int 2008; 73: 384–390.
13. Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular calcification. Lessons learned from the aorta. Arterioscler Thromb Vasc Biol 2006; 26: 1423–1430.
14. Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol 2010; 7: 528–536.
15. Neven E, De Schutter TM, De Broe ME et al. Cell biological and physicochemical aspects of arterial calcification. Kidney Int 2011; 79: 1166–1177.
16. Reynolds JL, Joannides AJ, Skepper JN et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857–2867.
17. Demer L, Tintut Y. The role of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification. Circ Res 2011; 108: 1482–1493.
18. Mody N, Parhani F, Sarafian TA et al. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med 2001; 31: 509–519.
19. Tanikawa T, Okaya Y, Tanikawa R et al. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK and upregulation of Runx2. J Vasc Res 2009; 46: 572–580.
20. Stubbs JR, Liu S, Tang W et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007; 18: 2116–2124.
21. Jaffe IZ, Tintut Y, Newell BF et al. Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol 2007; 27: 799–805.
22. Burton DG, Matsubara H, Ikeda K. Pathophysiology of vascular calcification: pivotal role of cellular senescence in vascular smooth muscle cells. Exp Gerontol 2010; 45: 819–824.
23. Nakano-Kurimoto R, Ikeda K, Uraoka M et al. Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating osteoblastic transition. Am J Physiol Heart Circ Physiol 2009; 297: H1673–H1684.
24. Liu Y, Drozdov I, Shroff R et al. Prenalin A accelerates vascular calcification via activation of the DNA damage response and senescence associated secretory phenotype in vascular smooth muscle cells. Circ Res 2013; 112: e99–e109.
25. Doherty TM, Asotra K, Fitzpatrick LA et al. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA 2003; 100: 11201–11206.
26. Shao JS, Sadhu J, Towler DA. Inflammation and the osteogenic regulation of vascular calcification. A review and perspective. Hypertension 2010; 55: 579–592.
27. Byon CH, Sun Y, Chen J et al. Runx2-upregulated receptor activator of nuclear factor κB ligand in calcifying smooth muscle cells promotes...
magnification and osteoelastic differentiation of macrophages. Arterioscler Thromb Vasc Biol 2011; 31: 1387–1396.

28. Panizo S, Cardus A, Encinas M et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4 dependent pathway. Circ Res 2009; 104: 1041–1048.

29. Aikawa E, Nahrendor Mf, Figueredo J-L et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation 2007; 116: 2841–2850.

30. Bostrom KI, Rajamannan NM, Towler DA. The regulation of valvular and vascular calcification by osteogenic morphogens. Circ Res 2011; 109: 564–577.

31. Shao J-S, Cheng S-L, Joyce M et al. Mx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005; 115: 1210–1220.

32. Al-Aly Z, Shao J-S, Lai C-F et al. Aortic Mx2-Wnt calcification cascade is regulated by TNF-α-dependent signals in diabetic Ldr−/− mice. Arterioscler Thromb Vasc Biol 2007; 27: 2589–2596.

33. Aikawa E, Aikawa M, Libby P et al. Arterial and aortic valve calcification abolished by elastolytic cathespin deficiency in chronic renal failure. Circulation 2009; 119: 1785–1794.

34. Tistra JS, Robinson AR, Wang L et al. NF-kB inhibition delays DNA damage-induced senescence and aging in mice. J Clin Investig 2012; 122: 2601–2612.

35. Ragnauth CD, Warren DT, Yiwen Liu Y et al. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 2010; 121: 2200–2210.

36. Carrero JJ, Stenvinkel P, Fellström B et al. Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. J Intern Med 2008; 263: 302–312.

37. Shanahan C, Croughamel MH, Kapustín A et al. Arterial calcification in chronic kidney disease: key role for calcium and phosphate. Circ Res 2011; 109: 697–711.

38. Zhao M-M, Xu M-J, Cai Y et al. Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate induced vascular calcification in vitro and in vivo. Kidney Int 2011; 79: 1071–1079.

39. Moe SM, Duan D, Hutson SM et al. Uremia induces the osteoblast differentiation factor Cbfα1 in human blood vessels. Kidney Int 2003; 63: 1003–1011.

40. Schoppet M, Shroff RC, Hofbauer LC et al. Exploring the biology of vascular calcification in chronic kidney disease: what’s clustering? Kidney Int 2012; 81: 384–390.

41. Luo G, Ducy P, McKee MD et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78–81.

42. Sweatt A, Sane DC, Hutson SM et al. Matrix GLA protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. J Thromb Haemost 2003; 1: 178–185.

43. Price PA, June HH, Buckley JR et al. Osteoprotegerin inhibits arthritis calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001; 21: 1610–1616.

44. Schafer C, Weiss A, Schwarz A et al. The serum protein alpha-2-Heremans-Schmid glycoprotein/fetuin-A is a systematically acting inhibitor of ectopic calcification. J Clin Investig 2003; 112: 357–366.

45. Lamoshvili K, Cobbs S, Hennigar RA et al. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol 2004; 15: 1392–1401.

46. Huang JC, Sakata T, Pfleger LL et al. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 2004; 19: 234–244.

47. Shao JS, Cheng SL, Charlton-Kachjian N et al. Teriparatide [human parathyroid hormone (1–34)] inhibits osteogenic vascular calcification in diabetes low density lipoprotein receptor-deficient mice. J Biol Chem 2003; 278: 50195–50200.

48. Kuro-o M. Klotho as a regulator of oxidative stress and senescence. Biochem Biophys Res Commun 2008; 389: 233–241.

49. Hu MC, Shl M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22: 124–136.

50. Lim K, Lu T-S, Molostov G et al. Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012; 125: 2243–2255.

51. Huang H, Virmani R, Younis H et al. The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation 2003; 103: 1051–1056.

52. Lin TC, Tintut Y, Lyman A et al. Mechanical response of a calcified plaque model to fluid shear force. Ann Biomed Eng 2006; 34: 1535–1541.

53. Kono K, Fuji H, Nakai K et al. Composition and plaque patterns of coronary culprit lesions and clinical characteristics of patients with chronic kidney disease. Kidney Int 2012; 82: 344–351.

54. O’Neil WC, Lomashvili KA, Malluche HH et al. Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int 2011; 79: 512–517.

55. Helas S, Goettsc H, Schoppet M et al. Inhibition of receptor activator of NF-κB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 2009; 175: 473–478.

56. Price PA, Roublick AM, Willamson MK. Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 2006; 70: 1577–1583.

57. Osako MK, Nakajami H, Kobeuchi N et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res 2010; 107: 466–475.

58. Kawata T, Nago N, Obi M et al. Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 2008; 74: 1270–1277.

59. Ng K, Hildreth C, Avolio AP et al. Angiotensin-converting enzyme inhibitor limits model of cystic renal disease pulse-wave velocity and aortic calcification in a rat. Am J Physiol Renal Physiol 2011; 301: F959–F966.

60. Voelk J, Alesutan L, Leibrock CB et al. Spironolactone ameliorates PTH1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Investig 2013; 123: 812–822.

61. Derwall M, Malhotra R, Lai CS et al. Inhibition of bone morphogenic protein signaling reduces vascular calcification and atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 613–622.

62. Chertow GM, Burke SK, Raggi P et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patient. Kidney Int 2002; 62: 245–252.

63. London GM, Marchais SJ, Guerin AP et al. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008; 19: 1827–1835.

64. The EVOLVE trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482–2494.

65. Schlieper G, Westenfeld R, Krüger T et al. Circulating nonphosphorylated carboxylated matrix GLA protein predicts survival in ESRD. J Am Soc Nephrol 2011; 22: 387–395.

66. Westenfeld R, Krüger T, Schlieper G et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialyzed patients: a random trial. Am J Kidney Dis 2012; 59: 186–195.